ClinicalTrials.gg
RecruitingNCT06503588JJ-change-UTIUpdated Aug 8, 2025

Ureteral Stent Exchange Abstention in Urinary Tract Infections

An observational study in Urinary Tract Infections and Urinary Catheterization, sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2025-08-08.

Sponsored by Central Hospital, Nancy, France · Observational

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
300
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Urinary Tract Infections with a site in France — 10 open to participants now, 11 under way, 1 of them phase 3. Urinary Tract Infections · France.

Planned enrollment
9th of 23
300 · median 200
Started
2024
with 2 others
Observational
23 of 58
5 open now
Primary completion
2025-03
later than 3 of 10 live
Registered
50th of 58
by date
Lead sponsor
2 of 58
Central Hospital, Nancy, France

Among the 58 studies in Urinary Tract Infections with a site in France, this one is the 9th largest by planned enrollment of the 23 observational ones that give a count, is one of 3 that started in 2024, is one of 23 observational ones, reaches primary completion later than 3 of the 10 other live ones, and was the 50th registered.

Urinary Tract Infections

808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

10 of the 58 studies in Urinary Tract Infections with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Urinary Tract Infections with a site in France, or all of them as a file.
02

Study summary

The Committee of Infectiology of the French Association of Urology (CIAFU) provided, for the first time in 2020, comprehensive guidelines for ureteral stent-associated urinary tract infections (USAUTI) prevention, diagnosis and treatment. Since evidence lacked in terms of appropriate treatment, guidelines could not support systematic change of US in case of USAUTI.

This study aims to evaluate whether "after guidelines group" patients treated for USAUTI had different occurrence of at least one relapse or recurrence than "before guidelines group".

03

Conditions studied

  • Urinary Tract Infections
  • Urinary Catheterization
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Groups will be selected from patients attending University Hospital of Nancy meeting the eligibility criteria during the period of inclusion running from January 1, 2018 to May 31, 2020 and from August 1, 2020 to December 31, 2022

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients with indwelling ureteral catheter
  • AND confirmed or probable urinary tract infection

Exclusion criteria

Exclusion Criteria:

  • Patient's opposition
  • History of ileal conduit urinary diversion
  • Second or more urinary tract infection during the study period
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Before guidelines

    Patients treated for ureteral stent associated urinary tract infection in the University Hospital of Nancy from January 1, 2018 to May 31, 2020

  • After guidelines

    Patients treated for ureteral stent associated urinary tract infection in the University Hospital of Nancy from August 1, 2020 to December 31, 2022

    Other: Guidelines promoting surgical abstention

Interventions

  • OtherGuidelines promoting surgical abstention

    Guidelines promoting surgical abstention

06

What researchers measure

Primary outcomes

  1. Relapse OR recurrence of urinary tract infection

    Time frame: 1 year

Secondary outcomes

  1. Nephro-urologic complication

    Acute kidney injury ; hematuria ; pain ; stent migration or incrustation

    Time frame: 1 year

  2. Infectious complication

    Sepsis or septic shock

    Time frame: 1 year

  3. In-hospital and 1-year mortality

    all cause death

    Time frame: 1 year

  4. Resort to Watch or Reserve antibiotics

    antibiotics' WHO classifcation

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Mar 2025, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2024
First posted
Jul 16, 2024
StartActual
Jul 1, 2024
Primary completionActual
Mar 1, 2025
CompletionEst.
Sep 1, 2025
Last update
Aug 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06503588
Responsible party
LEFEVRE Benjamin (MD. PhD., Central Hospital, Nancy, France) — Principal investigator
First posted
Jul 16, 2024
Start date
Jul 1, 2024
Primary completion
Mar 1, 2025
Completion
Sep 1, 2025 (estimated)
Last update
Aug 8, 2025

Study contacts

Benjamin Lefevre, M.D. PhD
Contact
b.lefevre@chru-nancy.fr
+33383154097
Tahani Sara
Contact
s.tahani@chru-nancy.fr
+33383154097
+33383154097 Lefevre, M.D. PhD
principal investigator · Central Hospital, Nancy, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion